Nick MaxfieldThe van der Schaar Lab’s eighth Revolutionizing Healthcare engagement session for the clinical community took place virtually on May 27, 2021.
This session was a roundtable with clinicians, focusing on personalized therapeutics and individualized treatment effects (ITE). Following a short presentation by Mihaela van der Schaar, a panel of four clinicians and the audience discussed a range of topics related to personalized therapeutics, including the limitations of existing clinical guidelines, and the potential for machine learning and AI to aid the development of more personalized and useful guidelines in healthcare.
Our panel for this session consisted of:
- Camelia Davtyan, MD FACP (Clinical professor of medicine, Division of General Internal Medicine, UCLA // Director of Women’s Health, UCLA Comprehensive Health Program)
- Eoin McKinney, MD PhD (University lecturer in renal medicine, University of Cambridge // Honorary consultant in nephrology and transplantation, Cambridge University Hospitals NHS Foundation Trust)
- Lucas Fleuren (PhD candidate, Artificial Intelligence, Laboratory for Critical Care Computational Intelligence, Amsterdam UMC // Resident, Department of Intensive Care Medicine, Amsterdam UMC)
- Neal Navani, PhD FRCP (Honorary associate professor, University College London // Consultant, Respiratory Medicine, UCL Hospitals NHS Foundation Trust)
Introduction – 0:00
Meet the roundtable panelists – 2:24
Declaration of interests – 3:28
Live presentation by Mihaela on personalized therapeutics/ITE – 4:53
Discussion among panelists on limitations of clinical guidelines – 24:39
Question for panelists on assessing reliability of counterfactuals [Karen Sayal] – 33:16
Discussion among panelists on potential role of AI/ML in personalized therapeutics – 38:25
Question for panelists on trade-offs between clinician domain knowledge and machine prediction [Zhiqiang Huo] – 44:06
Discussion among panelists on specific opportunities in personalized therapeutics – 46:00
Question for panelists on handling unusual patient features [Tom Coats] – 56:18
Proposal for demonstrating value of AI/ML personalized therapeutics [Henk van Weert] – 1:00:36
Intro to next sessions and note on CPD credits – 1:03:09
NOTE: This information was up-to-date at the time of the presentation but does not take into account material published since then.
Sign up for our upcoming sessions here.
Andreas Bedorf
Tim Schubert
Tim Oosterlinck
